Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics, Inc. ( ($MLYS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement. Mineralys Therapeutics sha...

Mineralys Therapeutics recently reported a first-quarter 2026 net loss of US$39.34 million and announced that it will present Phase 3 Launch-HTN data for its lead candidate lorundrostat in uncontrolled hypertension and chronic kidney disease at the European Meeting on Hypertension and ...

Melius Research reset its Micron share price target the same day shares dropped almost 6%. The move is unusual, and the reason behind it matters.

May 21, 2026 •By Motley Fool TranscribingWorkday WDAY Q1 2027 Earnings Call Transcript ... *Average returns of all recommendations since inception. Cost basis and return based on previous market day close. Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, ...

Mineralys Therapeutics CMO David Malcom exercised options for 417 shares at $15.44 and sold 417 shares at $27.55 under a Rule 10b5-1 plan, leaving 63,443 shares held.